The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi Lo (efavirenz, lamivudine, tenofovir) has been approved for marketing in China. The drug was awarded priority review status in May 2020 for use in human immunodeficiency virus type 1 (HIV-1) infection in adults and children weighing at least 35kg.
Symfi Lo: US Approval and Dosage
Symfi Lo, an antiretroviral therapy (ART), obtained a market nod in the US in February 2018. The first dosage of the efavirenz, lamivudine, tenofovir combo is 600mg, 300mg, and 300mg respectively, as opposed to Symfi Lo’s 400mg, 300mg, and 300mg.
China’s HIV/AIDS Treatment Guidelines
China’s HIV/AIDS diagnosis and treatment guidelines recommended in 2018 that for AIDS patients whose weight is less than 60kg, the dose of efavirenz should be adjusted from 600mg/day to 400mg/day, which helps to improve the therapeutic effect and reduce adverse reactions.-Fineline Info & Tech
